FibroBiologics files patent on cells that secrete GLP-1 peptides in body
The application covers engineered fibroblast, stem and immune cell spheroids designed to release GLP-1, GIP and GLP-2 class peptides after a single administration.
The wire
- 01FibroBiologics said Wednesday it filed a U.S. patent application for three-dimensional cell aggregates engineered to continuously secrete therapeutic peptides, explicitly covering GLP-1, GIP and GLP-2 classes.
- 02If it advances, the approach would target the injection burden, dose spikes and compliance gaps that shape current incretin prescribing and supply.
- 03This is a patent filing, not data; the company describes immune-evasive edits, safety switches and encapsulation as design features, with no clinical work disclosed. Shares traded near $1.11.
From the source
Read at aol.caEXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections
FibroBiologics Inc. (NASDAQ: FBLG ) on Wednesday filed a U.S. patent application for a cell-based platform designed to produce therapeutic peptides continuously inside the human body, offering a potential long-term alternative to traditional weight-loss and diabetes treatments.
